These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 16932282

  • 1. Do glucocorticoids affect outcome in Graves' disease following radioiodine therapy?
    Salvatore D, Fenzi G.
    Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):194-5. PubMed ID: 16932282
    [No Abstract] [Full Text] [Related]

  • 2. Endocrine ophthalmopathy and radioiodine therapy.
    Karlsson FA.
    Acta Oncol; 2006 Apr; 45(8):1046-50. PubMed ID: 17118837
    [Abstract] [Full Text] [Related]

  • 3. Qualitative and quantitative impact of protective glucocorticoid therapy on the effective 131I half-life in radioiodine therapy for Graves disease.
    Hautzel H, Pisar E, Yazdan-Doust N, Schott M, Beu M, Müller HW.
    J Nucl Med; 2010 Dec; 51(12):1917-22. PubMed ID: 21078788
    [Abstract] [Full Text] [Related]

  • 4. Graves' ophthalmopathy and 131I therapy.
    Marcocci C, Bartalena L, Tanda ML, Manetti L, Dell'Unto E, Mazzi B, Rocchi R, Barbesino G, Pinchera A.
    Q J Nucl Med; 1999 Dec; 43(4):307-12. PubMed ID: 10731781
    [Abstract] [Full Text] [Related]

  • 5. Oral steroid prophylaxis for Graves' orbitopathy after radioactive iodine treatment for Graves' disease is not only effective, but also safe.
    Rosetti S, Tanda ML, Veronesi G, Masiello E, Premoli P, Gallo D, Cusini C, Donati S, Sabatino J, Ippolito S, Piantanida E, Bartalena L.
    J Endocrinol Invest; 2020 Mar; 43(3):381-383. PubMed ID: 31587179
    [No Abstract] [Full Text] [Related]

  • 6. Treatment of Graves' hyperthyroidism--prognostic factors for outcome.
    Alfadda A, Malabu UH, El-Desouki MI, Al-Rubeaan KA, Al-Ruhaily AD, Fouda MA, Al-Maatouq MA, Sulimani RA.
    Saudi Med J; 2007 Feb; 28(2):225-30. PubMed ID: 17268701
    [Abstract] [Full Text] [Related]

  • 7. Glucocorticoid therapy of Graves' ophthalmopathy.
    Bartalena L, Marocci C, Bogazzi F, Bruno-Bossio G, Pinchera A.
    Exp Clin Endocrinol; 1991 May; 97(2-3):320-7. PubMed ID: 1915650
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinical practice. Graves' ophthalmopathy.
    Bartalena L, Tanda ML.
    N Engl J Med; 2009 Mar 05; 360(10):994-1001. PubMed ID: 19264688
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Radioiodine-Associated Exacerbation of Graves' Orbitopathy in the Japanese Population: Randomized Prospective Study.
    Watanabe N, Noh JY, Kozaki A, Iwaku K, Sekiya K, Kosuga Y, Matsumoto M, Suzuki M, Yoshihara A, Ohye H, Kobayashi S, Kunii Y, Mukasa K, Sugino K, Inoue T, Ito K.
    J Clin Endocrinol Metab; 2015 Jul 05; 100(7):2700-8. PubMed ID: 25965082
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Thyroid associated orbitopathy--medication, radioiodine or operation?
    Czarnywojtek A, Zgorzalewicz-Stachowiak M, Stangierski A, Florek E, Zdanowska J, Katarzyna H, Andrzejewska M, Ruchała M.
    Przegl Lek; 2012 Jul 05; 69(10):1140-3. PubMed ID: 23421110
    [Abstract] [Full Text] [Related]

  • 14. Post-radioiodine De Novo Onset Graves' Ophthalmopathy: Case Reports and a Review of the Literature.
    Batra R, Krishnasamy SK, Buch H, Sandramouli S.
    Semin Ophthalmol; 2015 May 05; 30(3):227-31. PubMed ID: 24409943
    [Abstract] [Full Text] [Related]

  • 15. Radioiodine therapy of Graves' hyperthyroidism in patients without pre-existing ophthalmopathy: can glucocorticoids prevent the development of new ophthalmopathy?
    Dederichs B, Dietlein M, Jenniches-Kloth B, Schmidt M, Theissen P, Moka D, Schicha H.
    Exp Clin Endocrinol Diabetes; 2006 Jul 05; 114(7):366-70. PubMed ID: 16915539
    [Abstract] [Full Text] [Related]

  • 16. Glucocorticoid administration for Graves' hyperthyroidism treated by radioiodine. A questionnaire survey among members of the European Thyroid Association.
    Lazarus JH, Bartalena L, Marcocci C, Kahaly GJ, Krassas G, Wiersinga WM, EUGOGO (European Group on Graves' Orbitopathy).
    J Endocrinol Invest; 2010 Jun 05; 33(6):409-13. PubMed ID: 20101098
    [Abstract] [Full Text] [Related]

  • 17. Comparative Efficacy of Four Treatments in Patients with Graves' Disease: a Network Meta-analysis.
    Ren Z, Qin L, Wang JQ, Li Y, Li J, Zhang RG.
    Exp Clin Endocrinol Diabetes; 2015 May 05; 123(5):317-22. PubMed ID: 25988881
    [Abstract] [Full Text] [Related]

  • 18. [Treatment with iodine radioisotopes and thyroid-associated ophthalmopathy in Graves' disease].
    Rasmussen AK, Feldt-Rasmussen UF.
    Ugeskr Laeger; 1999 Oct 25; 161(43):5933-4. PubMed ID: 10778332
    [No Abstract] [Full Text] [Related]

  • 19. Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review.
    Acharya SH, Avenell A, Philip S, Burr J, Bevan JS, Abraham P.
    Clin Endocrinol (Oxf); 2008 Dec 25; 69(6):943-50. PubMed ID: 18429949
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.